Snap launched AR glasses at $2,195, above the $799 Ray‑Ban Meta version. The price depressed the stock, which eked out a 0.8% gain after a 10% drop last session. Meanwhile, Essilor Luxottica sealed a hardware tie‑up with Applied Materials, a move analysts say secures its AR lead. Shares fell 2.3%. Analysts view the gap as a barrier to adoption, leaving Essilor’s cheaper models attractive to consumers.

Swiss dental‑implant leader Straumann raised its 2026 profitability outlook, signalling a structurally stronger earnings profile. Jefferies notes the firm now controls about 35% of the 6‑billion‑franc Swiss implant market, bolstered by a cloud‑based digital platform. Despite headwinds in China and the U.S., the stock surged 9.3% on the news.

Deutsche Bank cut its rating on Italian diagnostics group Dia Sorin to sell, citing overly optimistic 2026 guidance and a risky rollout of its NES molecular‑diagnostics platform. The bank lowered the target price to 58 euros from 62 euros, prompting a 1.3% decline to 66.44 euros at Tuesday’s close.

The mixed results underscore volatility in health‑care tech stocks as pricing strategies clash with growth ambitions. While Snap battles consumer price resistance, European players lean on strategic partnerships and digital upgrades to boost margins. Investors are weighing short‑term earnings swings against longer‑term platform adoption curves.